Repression of intestinal drug metabolizing enzymes by the SV40 large T antigen

Oncogene

Volumn 26, Issue 35, 2007, Pages 5124-5131

  Saenz Robles M T ^a   Toma, D ^a   Cantalupo, P ^a   Zhou, J ^a   Gong, H ^a   Edwards, C ^a   Pipas, J M ^a   Xie, W ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Cytochrome P450; Retinoblastoma; SV40 T antigen

Indexed keywords

CARCINOGEN; CYTOCHROME P450; CYTOCHROME P450 3A11; DRUG METABOLIZING ENZYME; INTESTINE ENZYME; MESSENGER RNA; RETINOBLASTOMA PROTEIN; SV40 LARGE T ANTIGEN; UNCLASSIFIED DRUG; VIRUS LARGE T ANTIGEN; XENOBIOTIC AGENT;

ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; DETOXIFICATION; DOWN REGULATION; ENZYME REPRESSION; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE INACTIVATION; INTESTINE EPITHELIUM CELL; LIVER; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN MOTIF; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTIGENS, POLYOMAVIRUS TRANSFORMING; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION; INTESTINAL MUCOSA; LIVER; MALE; MEMBRANE PROTEINS; METABOLIC DETOXICATION, DRUG; MICE; MICE, TRANSGENIC; SIMIAN VIRUS 40; XENOBIOTICS;

EID: 34547638046     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210310     Document Type: Article

References (31)

1. Ahuja D, Saenz-Robles MT, Pipas JM. (2005). SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene 24: 7729-7745.
2. Bosco EE, Mayhew CN, Hennigan RF, Sage J, Jacks T, Knudsen ES. (2004). RB signaling prevents replication-dependent DNA double-strand breaks following genotoxic insult. Nucleic Acids Res 32: 25-34.
3. Blumberg B, Sabbagh W, Juguilon H, Bolado Jr J, Ong ES, Evans RM. (1998). SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev 12: 3195-3205.
4. Chandrasekaran C, Coopersmith CM, Gordon JI. (1996). Use of normal and transgenic mice to examine the relationship between terminal differentiation of intestinal epithelial cells and accumulation of their cell cycle regulators. J Biol Chem 271: 28414-28421.
5. Chrivia JC, Kwok RPS, Lamb N, Hagiwara M, Montminy MR, Goodman RH. (1993). Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature 365: 855-859.
6. Cohn SM, Simon TC, Roth KA, Birkenmeier EH, Gordon JI. (1992). Use of transgenic mice to map cis-acting elements in the intestinal fatty acid binding protein gene (Fabpi) that control its cell lineage-specific and regional patterns of expression along the duodenal-colonic and crypt-villus axes of the gut epithelium. J Cell Biol 119: 27-44.
7. DeCaprio JA, Ludlow JW, Figge J, Shew JY, Huang CM, Lee WH et al. (1988). SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 54: 275-283.
8. Ewen ME, Ludlow JW, Marsilio E, DeCaprio JA, Millikan RC, Cheng SH et al. (1989). An N-terminal transformation-governing sequence of SV40 large T antigen contributes to the binding of both p110Rb and a second cellular protein, p120. Cell 58: 257-267.
9. Hauft SM, Kim SH, Schmidt GH, Pease S, Rees S, Harris S et al. (1992). Expression of SV-40 T antigen in the small intestinal epithelium of transgenic mice results in proliferative changes in the crypt and reentry of villus-associated enterocytes into the cell cycle but has no apparent effect on cellular differentiation programs and does not cause neoplastic transformation. J Cell Biol 117: 825-839.
10. Kim RB. (2003). Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. Eur J Clin Invest 33: 1-5.
11. Kim SH, Roth KA, Coopersmith CM, Pipas JM, Gordon JI. (1994). Expression of wild-type and mutant simian virus 40 large tumor antigens in villus-associated enterocytes of transgenic mice. Proc Natl Acad Sci USA 91: 6914-6918.
12. Kim SH, Roth KA, Moser AR, Gordon JI. (1993). Transgenic mouse models that explore the multistep hypothesis of intestinal neoplasia. J Cell Biol 123: 877-893.
13. Kullak-Ublick GA. (2003). ABC transporter regulation by bile acids: where PXR meets FXR. J Hepatol 39: 628-630.
14. Kliewer SA, Moore JT, Wade L, Staudinger JL, Jones MA, McKee DD et al. (1998). An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92: 73-82.
15. Liu F, Song YK, Liu D. (1999). Hydrodynamic-based transfection in animals by systemic administration of plasmid DNA. Gene Therapy 6: 1258-1266.
16. Maurel P. (1996). The CYP3 family. In: Ioannides C (ed). Cytochrome P450: Metabolic and Toxicological Aspects. CRC Press: Boca Raton, FL, pp 241-270.
17. Mayhew CN, Perkin LM, Zhang X, Sage J, Jacks T, Knudsen ES. (2004). Discrete signaling pathways participate in RB-dependent responses to chemotherapeutic agents. Oncogene 23: 4107-4120.
18. Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y. (2003). Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 55: 425-461.
19. McFadyen MC, McLeod HL, Jackson FC, Melvin WT, Doehmer J, Murray GI. (2001). Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. Biochem Pharmacol 62: 207-212.
20. Oyama T, Kagawa N, Kunugita N, Kitagawa K, Ogawa M, Yamaguchi T et al. (2004). Expression of cytochrome P450 in tumor tissues and its association with cancer development. Front Biosci 9: 1967-1976.
21. Puga A, Marlowe J, Barnes S, Chang CY, Maier A, Tan Z et al. (2002). Role of the aryl hydrocarbon receptor in cell cycle regulation. Toxicology 181-182: 171-177.
22. Renton KW. (2004). Cytochrome P450 regulation and drug biotransformation during inflammation and infection. Curr Drug Metab 5: 235-243.
23. Rodriguez-Antona C, Ingelman-Sundberg M. (2006). Cytochrome P450 pharmacogenetics and cancer. Oncogene 26: 1679-1691.
24. Rooseboom M, Commandeur JN, Vermeulen NP. (2004). Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol Rev 56: 53-102.
25. Saini SP, Mu Y, Gong H, Toma D, Uppal H, Ren S et al. (2005). Dual role of orphan nuclear receptor pregnane X receptor in bilirubin detoxification in mice. Hepatology 41: 497-505.
26. Srinivasan A, McClellan AJ, Vartikar J, Marks I, Cantalupo P, Li Y, Whyte P et al. (1997). The amino-terminal transforming region of simian virus 40 large T and small T antigens functions as a J domain. Mol Cell Biol 17: 4761-4773.
27. Sompayrac L. (1997). SV40 and adenovirus may act as cocarcinogens by downregulating glutathione S-transferase expression. Virology 233: 130-135.
28. Uppal H, Toma D, Saini SPS, Ren S, Jones TJ, Xie W. (2005). Combined loss of orphan receptors PXR and CAR heightens the sensitivity to toxic bile acids in mice. Hepatology 41: 168-176.
29. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC et al. (2004). Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32: 1201-1208.
30. Xie W, Barwick JL, Simon CM, Downes M, Blumberg B, Neuschwander-Tetri BA et al. (2000). Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 406: 435-439.
31. Xie W, Uppal H, Saini SPS, Mu Y, Little JM, Radominska-Pandya A et al. (2004). Orphan nuclear receptor-mediated xenobiotic regulation in drug metabolism and human diseases. Drug Discov 9: 442-449.